Pengyang Medical Secures Tens of Millions of RMB in Series A Funding Led by CCB Healthcare Growth Fund

VCBeat (WeChat ID: vcbeat) has learned that on July 24, Pengyang Medical, a globally leading manufacturer of dynamic ECG medical devices, announced the completion of a new round of tens of millions of yuan in Series A financing. The investor in this round is CCB Medical Growth Fund, with Zero2IPO Project Factory serving as the exclusive financial advisor. The proceeds from this financing will be used for marketing network expansion, R&D and regulatory approval of product series, academic promotion and brand building, as well as product and technology acquisitions.

Pengyang Medical is a medical device manufacturer specializing in the detection of cardiovascular diseases. Its product portfolio includes 18-lead/12-lead Holter monitors, ambulatory blood pressure monitoring systems, dynamic ECG networks, and multi-parameter Holter devices. Its core innovative product is the “18-Lead Full-Information Dynamic ECG Analysis System,” namely the 18-lead Holter product MedSun-V18. This is not only a leading exclusive product in China but also globally.

Currently, the number of people with cardiovascular disease in China has reached 290 million. Cardiovascular disease accounts for more than 40% of resident deaths, far exceeding the mortality rates of tumors and other diseases. The burden of cardiovascular disease is increasingly heavy, becoming a major public health issue.

However, the current domestic dynamic electrocardiography field faces widespread pain points:

I. The 12-lead Holter monitor fails to detect myocardial electrical signals from the true posterior wall of the left ventricle and the right ventricle, which can easily lead to missed or incorrect diagnoses and is detrimental to the establishment of a large-scale electrocardiographic database.

II. Inconvenient for patients to wear; hardware exhibits poor anti-interference capability, inaccurate data acquisition, and overly vague automated diagnostic results.

3. The software analysis system is overly cumbersome, resulting in excessively long interpretation times for physicians and negatively impacting work efficiency.

Addressing these pain points, Pengyang Medical has leveraged years of R&D investment and collaborated with numerous renowned hospitals, universities, and research institutions in China to develop a globally exclusive innovative product with independent proprietary intellectual property rights. This breakthrough thoroughly resolves the long-standing challenge in traditional dynamic ECG diagnosis of failing to achieve comprehensive, full-information coverage of cardiac activity. Its fully intelligent pre-analysis system rapidly generates automated diagnostic conclusions, saving physicians over 50% of interpretation time and significantly enhancing workflow efficiency. By providing more comprehensive and accurate scientific evidence for precise clinical diagnosis and treatment, it also offers patients a more convenient and comfortable wearing experience.

The Chinese Society of Electrocardiology has jointly established the “Pengyang Fund” with Pengyang Medical to promote the development of electrocardiology in China and popularize the application of 18-lead Holter products. Academic promotion conferences have already been held in multiple regions, including Beijing, Shandong, Henan, Fujian, and Hebei. The product series has received high recognition and acclaim from numerous electrocardiology experts and local cardiologists.

Regarding this round of financing, Han Jing, Partner at Project Factory and Zero2IPO Capital, stated: “Project Factory is honored to have facilitated the completion of this financing. In the current domestic landscape characterized by intense price competition among enterprises, it is particularly gratifying to witness a company with revolutionary technological innovations stand out. Its core products and technologies are at the forefront globally, and it has been consistently striving to drive innovation in China’s medical technology and enhance diagnostic and therapeutic standards. Project Factory is committed to providing startups with comprehensive ‘online + offline’ financing services, maximizing resource integration to support their sustainable development.”

CCB Medical Growth Fund is a private equity fund under CCB International, operating on a market-oriented basis and focusing on investments in high-quality early- to growth-stage healthcare companies. Leveraging the Kunshan High-Tech Industrial Development Zone, the fund capitalizes on CCB International’s synergistic advantages in investment banking and its professional healthcare investment team, while integrating China Minsheng Future’s premium healthcare industry resources. It precisely selects technology commercialization projects within the healthcare sector, accelerates the development of innovative healthcare enterprises, and provides comprehensive post-investment value-added services to portfolio companies, committed to achieving mutual growth and value creation with enterprises and shareholders.